“Today is a great day for science and humanity,” opens Pfizer Chief Executive Albert Bourla. Pfizer’s COVID-19 Vaccine reaches a breakthrough for the pandemic battle the world is currently facing. Reports say that Pfizer Inc’s PFE.N reached more than 90% effectivity based on initial trial results giving hope to millions of people infected with the disease.
No serious safety concerns had arised during the clinical tests according to Pfizer and German partner BioNTech SE 22UAy.F and they are planning to ask for U.S. emergency use of authorization so that the vaccine can be available to the public by December this year. However, U.S. Health and Human Services Secretary, Alex Azar, explains that it would take several weeks for U.S. regulator to receive and process the data before the vaccine can be approved for worldwide use. An estimate of two-month study for follow-up safety data to make sure there will be no side effects to appear after its use.
Various experts are requesting to see the full trial data, however the preliminary results are showing positive effects against the coronavirus. A professor from emerging infectious diseases at the University of Oxford, Peter Horby, said that Pfizer’s news is a “relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general.”
There are a lot of factors to consider for the vaccine like ethnicity, gender, age and longevity of immunity that should be researched to assure the vaccine is generally effective for everyone.
Dr. Anthony Fauci told CNN in an interview that Pfizer’s “vaccine is more than 90% effective, which is extraordinary.”
If Pfizer’s vaccine gets approved, the companies assure 50 million doses which can save 25 Million infected patients this year and produce 1.3 billion doses for the year 2021. If their plans pushes through, a lot of economies can start to reopen and hospitals who have been working over-time having over-capacity patients to tend to, can finally breathe.